Additionally, GAT107 resulted in a 12% (HDs) and 18% (MS patients) decrease in IL-6 secretion, and ACh resulted in a 14% (HDs) and 12% (MS patients) decrease in IL-6 secretion. Here, IL6 is linked to myeloid sarcoma.